Efficacy and safety of upadacitinib in refractory interstitial lung disease with idiopathic inflammatory myopathies: a retrospective study.
To assess the efficacy and safety of upadacitinib (UPA) in patients with refractory idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) following conventional therapy failure. We conducted a single-centre retrospective cohort study of IIM-ILD patients…